Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this prospective, interventional, multicentre, single-arm performance objective study is to evaluate efficacy and safety of Cratos™ Branch Stent Graft System in treatment of lesions (dissection, IMH and PAU in descending aorta. The main question\[s\] it aims to answer are: * 30-day all-cause Mortality rate * Composite of the following events from the time of enrolment through 12-month: * Device Technical Success * Absence of: Aortic rupture, Lesion-related mortality, Disabling Stroke, Permanent paraplegia, Permanent paraparesis, New onset renal failure requiring permanent dialysis, Additional unanticipated post-procedural surgical or interventional procedure related to the device, procedure, or withdrawal of the device system Participants will come for hospital office visits 1, 6, 12, 24-, 36-, 48- and 60-months post-procedure for the following, but not limited to assessments: * Physical examination * Modified Rankin scale * Tarlov scoring scale * CTA

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Presence of thoracic aortic pathology (Dissection, including IMH and ULP; and PAU) deemed to warrant surgical repair which requires proximal graft placement in Zone 2

• Age ≥18 years at time of informed consent signature

• Informed Consent Form (ICF) is signed by Subject or legal representative

• Must have appropriate proximal aortic landing zone, defined as:

‣ Landing zone inner diameters between 23-41 mm

⁃ The length of landing zone ≥15mm

⁃ Landing without heavily calcified or heavily thrombosed

⁃ Dissection Patients: Primary entry tear must be distal to LSA, and proximal extent of the proximal landing zone must not be dissected.

⁃ For patients with prior replacement of the ascending aorta and/or aortic arch by a surgical graft, there must be at least 2 cm of landing zone proximal to the most distal anastomosis site.

• Must have appropriate LSA landing zone, defined as:

‣ Inner diameters of LSA 5-14 mm

⁃ Minimum length of Left subclavian artery is 25 mm

⁃ Target branch vessel landing zone must be in native aorta that cannot be severely tortuous , aneurysmal, dissected, heavily calcified, or heavily thrombosed.

• Must have appropriate distal aortic landing zone, defined as:

‣ Aortic inner diameters between 18-44 mm

⁃ Landing zone cannot be heavily calcified, or heavily thrombosed.

⁃ For isolated PAU, outer curvature length must be ≥ 2cm proximal to the celiac artery

⁃ Landing zone in native aorta

Locations
Other Locations
Switzerland
University Hospital Zurich
RECRUITING
Zurich
Contact Information
Primary
Jing Wang
jing.wang@endovastec.com
3105283618
Time Frame
Start Date: 2024-03-08
Estimated Completion Date: 2031-12
Participants
Target number of participants: 130
Treatments
Experimental: TEVAR
Thoracic Endovascular Repair (TEVAR) provides a minimally invasive treatment option for descending thoracic aorta (DTA) pathologies.
Sponsors
Collaborators: Qmed Consulting A/S
Leads: Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd

This content was sourced from clinicaltrials.gov